Cargando…
A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients
BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242862/ https://www.ncbi.nlm.nih.gov/pubmed/37031458 http://dx.doi.org/10.1002/cam4.5857 |
_version_ | 1785054310686523392 |
---|---|
author | Muller Bark, Juliana Karpe, Avinash V. Doecke, James D. Leo, Paul Jeffree, Rosalind L. Chua, Benjamin Day, Bryan W. Beale, David J. Punyadeera, Chamindie |
author_facet | Muller Bark, Juliana Karpe, Avinash V. Doecke, James D. Leo, Paul Jeffree, Rosalind L. Chua, Benjamin Day, Bryan W. Beale, David J. Punyadeera, Chamindie |
author_sort | Muller Bark, Juliana |
collection | PubMed |
description | BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients. METHODS: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression‐free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole‐mouth and oral rinse) and plasma samples was conducted utilising LC‐QqQ‐MS and LC‐QTOF‐MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO‐based graphic network analyses. RESULTS: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic‐AMP, 3‐hydroxy‐kynurenine, dihydroorotate, UDP and cis‐aconitate were elevated, compared to patients with favourable outcomes during pre‐and post‐surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group. CONCLUSION: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required. |
format | Online Article Text |
id | pubmed-10242862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102428622023-06-07 A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients Muller Bark, Juliana Karpe, Avinash V. Doecke, James D. Leo, Paul Jeffree, Rosalind L. Chua, Benjamin Day, Bryan W. Beale, David J. Punyadeera, Chamindie Cancer Med RESEARCH ARTICLES BACKGROUND: Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients. METHODS: Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression‐free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole‐mouth and oral rinse) and plasma samples was conducted utilising LC‐QqQ‐MS and LC‐QTOF‐MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO‐based graphic network analyses. RESULTS: Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic‐AMP, 3‐hydroxy‐kynurenine, dihydroorotate, UDP and cis‐aconitate were elevated, compared to patients with favourable outcomes during pre‐and post‐surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group. CONCLUSION: Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required. John Wiley and Sons Inc. 2023-04-09 /pmc/articles/PMC10242862/ /pubmed/37031458 http://dx.doi.org/10.1002/cam4.5857 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Muller Bark, Juliana Karpe, Avinash V. Doecke, James D. Leo, Paul Jeffree, Rosalind L. Chua, Benjamin Day, Bryan W. Beale, David J. Punyadeera, Chamindie A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title | A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title_full | A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title_fullStr | A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title_full_unstemmed | A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title_short | A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
title_sort | pilot study: metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242862/ https://www.ncbi.nlm.nih.gov/pubmed/37031458 http://dx.doi.org/10.1002/cam4.5857 |
work_keys_str_mv | AT mullerbarkjuliana apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT karpeavinashv apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT doeckejamesd apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT leopaul apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT jeffreerosalindl apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT chuabenjamin apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT daybryanw apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT bealedavidj apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT punyadeerachamindie apilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT mullerbarkjuliana pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT karpeavinashv pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT doeckejamesd pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT leopaul pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT jeffreerosalindl pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT chuabenjamin pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT daybryanw pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT bealedavidj pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients AT punyadeerachamindie pilotstudymetabolicprofilingofplasmaandsalivasamplesfromnewlydiagnosedglioblastomapatients |